Probiotics and Diseases of the Genitourinary Tract

Gregor Reid

doi:10.1128/9781555815462.ch21

Chapter 21 : Probiotics and Diseases of the Genitourinary Tract

VIEW AFFILIATIONS HIDE AFFILIATIONS

Affiliations: 1: Canadian R&D Centre for Probiotics, Lawson Health Research Institute, F2–116, 268 Grosvenor Street, London, Ontario, N6A 4V2, Canada

Content Type: Monograph

Publication Year: 2008

Category: Clinical Microbiology

Book DOI: 10.1128/9781555815462

Chapter DOI: 10.1128/9781555815462.ch21

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:

Probiotics and Diseases of the Genitourinary Tract, Page 1 of 2

< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555815462/9781555814038_Chap21-1.gif /docserver/preview/fulltext/10.1128/9781555815462/9781555814038_Chap21-2.gif

Abstract:

Numerous diseases occur in the genitourinary tract of men, women, and children. These disorders cover the gamut of infection, incontinence, cancer, inflammatory problems, and anatomical malfunctions in the urethra, bladder, kidney, prostate, vulva, vagina, cervix, and uterus. The potential for probiotics to counter these ailments is not restricted to infection, but it is in this area that most of the research to date has been done. This chapter begins with conditions under which there is somewhat of a rationale for probiotics to affect the urogenital tract, but for which actual data are sparse. The main goal of probiotics applications is to prevent genitourinary tract infections by populating the vagina with lactobacilli after antifungal agents have reduced the yeast count. Probiotics repopulate the genitourinary tract, compete with other bacteria, and are flushed from the host, necessitating regular, repeated administration. A study was performed to examine the ability of probiotics to prevent bacterial vaginosis (BV) and yeast vaginitis in patients receiving antibiotic therapy. Widespread and growing interest in the use of probiotics for urogenital health has served as an impetus for numerous research studies.

Citation: Reid G. 2008. Probiotics and Diseases of the Genitourinary Tract, p 271-284. In Versalovic J, Wilson M (ed), Therapeutic Microbiology. ASM Press, Washington, DC. doi: 10.1128/9781555815462.ch21

Highlighted Text: Show | Hide

Full text loading...

Figures

Probiotics and Diseases of the Genitourinary Tract

[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555815462.ch21-1,webId=/content/author/10.1128/9781555815462.ch21-1,properties={foaf_givenname=Gregor, foaf_name=Gregor Reid, foaf_surname=Reid, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555815462.ch21-aff1]]}]]

/content/10.1128/9781555815462.ch21.ch21fig01

Figure 1

This diagram illustrates that ingestion of probiotic organisms has the potential to affect other parts of the host, either through direct passage to the genitourinary tract or through indirect effects on the host.

10.1128/9781555815462/ch21fig1_thmb.gif

10.1128/9781555815462/ch21fig1.gif

Figure 1

References

/content/book/10.1128/9781555815462.ch21

1. Allsworth, J. E., and, J. F. Peipert. 2007. Prevalence of bacterial vaginosis: 2001–2004 National Health and Nutrition Examination Survey data. Obstet. Gynecol. 109: 114– 120.

2. Amsel, R.,, P. A. Totten,, C. A. Spiegel,, K. C. Chen,, D. Eschenbach, and, K. K. Holmes. 1983. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am. J. Med. 74: 14– 22.

3. Anderson, G. G.,, S. M. Martin, and, S. J. Hultgren. 2004. Host subversion by formation of intracellular bacterial communities in the urinary tract. Microbes Infect. 6: 1094– 1101.

4. Anukam, K. C.,, E. O. Osazuwa,, I. Ahonkhai,, and G. Reid. 2006a. Lactobacillus vaginal microbiota of women attending a reproductive health care service in Benin city, Nigeria. Sex. Transm. Dis. 33: 59– 62.

5. Anukam, K. C.,, E. O. Osazuwa,, I. Ahonkhai,, and G. Reid. 2005. Association between absence of vaginal lactobacilli PCR products and Nugent scores interpreted as bacterial vaginosis. Trop. J. Obstet. Gynaecol. 22: 103– 107.

6. Anukam, K. C.,, E. Osazuwa,, G. I. Osemene,, F. Ehigiagbe,, A. W. Bruce,, and G. Reid. 2006b. Clinical study comparing probiotic Lactobacillus GR-1 and RC-14 with metronidazole vaginal gel to treat symptomatic bacterial vaginosis. Microbes Infect. 8: 2772– 2776.

7. Anukam, K. C.,, E. O. Osazuwa,, B. E. Osadolor,, A. W. Bruce,, and G. Reid. 2008. Yogurt containing probiotic Lactobacillus rhamnosus GR-1 and L. reuteri RC-14 helps resolve moderate diarrhea and increases CD4 count in HIV/AIDS patients. J. Clin. Gastroenterol. 42: 239– 243.

8. Arundel, C., and, J. H. Lewis. 2007. Drug-induced liver disease in 2006. Curr. Opin. Gastroenterol. 23: 244– 254.

9. Austin, M. N.,, R. H. Beigi,, L. A. Meyn, and, S. L. Hillier. 2005. Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole. J. Clin. Microbiol. 43: 4492– 4497.

10. Baerheim, A.,, E. Larsen, and, A. Digranes. 1994. Vaginal application of lactobacilli in the prophylaxis of recurrent lower urinary tract infection in women. Scand. J. Prim. Health Care 12: 239– 243.

11. Bruce, A. W.,, P. Chadwick,, A. Hassan, and, G. F. VanCott. 1973. Recurrent urethritis in women. Can. Med. Assoc. J. 108: 973– 976.

12. Bruce, A. W.,, G. Reid,, J. A. McGroarty,, M. Taylor,, and C. Preston. 1992. Preliminary study on the prevention of recurrent urinary tract infections in ten adult women using intravaginal lactobacilli. Int. Urogynecol. J. 3: 22– 25.

13. Bruce, A. W., and, G. Reid. 1988. Intravaginal instillation of lactobacilli for prevention of recurrent urinary tract infections. Can. J. Microbiol. 34: 339– 343.

14. Burton, J. P.,, E. Devillard,, P. A. Cadieux,, J.-A. Hammond,, and G. Reid. 2004. Detection of Atopobium vaginae in postmenopausal women by cultivation-independent methods warrants further investigation. J. Clin. Microbiol. 42: 1829– 1831.

15. Busscher, H. J., and, H. C. van der Mei. 1997. Physico-chemical interactions in initial microbial adhesion and relevance for biofilm formation. Adv. Dent. Res. 11: 24– 32.

16. Busscher, H. J.,, C. G. van Hoogmoed,, G. I. Geertsema-Doornbusch, M. van der Kuijl-Booij, and, H. C. van der Mei. 1997. Streptococcus thermophilus and its biosurfactants inhibit adhesion by Candida spp. on silicone rubber. Appl. Environ. Microbiol. 63: 3810– 3817.

17. Cauci, S.,, S. Guaschino,, D. De Aloysio,, S. Driussi,, D. De Santo,, P. Penacchioni,, and F. Quadrifoglio. 2003. Interrelationships of interleukin-8 with interleukin-1beta and neutrophils in vaginal fluid of healthy and bacterial vaginosis positive women. Mol. Hum. Reprod. 9: 53– 58.

18. Cauci, S.,, J. Hitti,, C. Noonan,, K. Agnew,, F. Quadrifoglio,, S. L. Hillier, and, D. A. Eschenbach. 2002. Vaginal hydrolytic enzymes, immunoglobulin A against Gardnerella vaginalis toxin, and risk of early preterm birth among women in preterm labor with bacterial vaginosis or intermediate flora. Am. J. Obstet. Gynecol. 187: 877– 881.

19. Chan, R. C. Y.,, A. W. Bruce, and, G. Reid. 1984. Adherence of cervical, vaginal and distal urethral normal microbial flora to human uroepithelial cells and the inhibition of adherence of uropathogens by competitive exclusion. J. Urol. 131: 596– 601.

20. Chan, R. C. Y.,, G. Reid,, R. T. Irvin,, A. W. Bruce, and, J. W. Costerton. 1985. Competitive exclusion of uropathogens from uroepithelial cells by Lactobacillus whole cells and cell wall fragments. Infect. Immun. 47: 84– 89.

21. Cherpes, T. L.,, L. A. Meyn,, M. A. Krohn, and, S. L. Hillier. 2003. Risk factors for infection with herpes simplex virus type 2: role of smoking, douching, uncircumcised males, and vaginal flora. Sex. Transm. Dis. 30: 405– 410.

22. Cook, R. L.,, R. J. Harris, and, G. Reid. 1988. Effect of culture media and growth phase on the morphology of lactobacilli and on their ability to adhere to epithelial cells. Curr. Microbiol. 17: 159– 166.

23. Corr, S. C.,, Y. Li,, C. U. Riedel,, P. W. O’Toole,, C. Hill, and, C. G. Gahan. 2007. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc. Natl. Acad. Sci. USA 104: 7617– 7621.

24. Dani, C.,, R. Biadaioli,, G. Bertini,, E. Martelli, and, F. F. Rubaltelli. 2002. Probiotics feeding in prevention of urinary tract infection, bacterial sepsis and necrotizing enterocolitis in preterm infants. A prospective double-blind study. Biol. Neonate 82: 103– 108.

25. Darouiche, R. O.,, J. I. Thornby,, C. Cerra-Stewart,, W. H. Donovan, and, R. A. Hull. 2005. Bacterial interference for prevention of urinary tract infection: a prospective, randomized, placebo-controlled, double-blind pilot trial. Clin. Infect. Dis. 41: 1531– 1534.

26. Dasgupta, M. K. 2002. Biofilms and infection in dialysis patients. Semin. Dial. 15: 338– 346.

27. Donder, G. G.,, A. Vereecken,, E. Bosmans,, A. Dekeersmaecker,, G. Salembier,, and B. Spitz. 2002. Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. BJOG 109: 34– 43.

28. Elwood, C.,, G. Reid, and, J. Jass. 2006. Characterization of the interaction between uropathogenic E. coli and probiotic Lactobacillus through auto-inducer-2 signaling. MSc thesis. University of Western Ontario, London, Ontario, Canada.

29. Ernst, E. J.,, M. E. Ernst,, J. D. Hoehns, and, G. R. Bergus. 2005. Women’s quality of life is decreased by acute cystitis and antibiotic adverse effects associated with treatment. Health Qual. Life Outcomes 3:45.

30. Fallagas, M. E.,, G. I. Betsi, and, S. Athanasiou. 2007. Probiotics for the treatment of women with bacterial vaginosis. Clin. Microbiol. Infect. 13: 657– 664.

31. FAO/WHO. 2001. Evaluation of Health and Nutritional Properties of Powder Milk and Live Lactic Acid Bacteria. Food and Agriculture Organization of the United Nations and World Health Organization Expert Consultation Report. ftp://ftp.fao.org/docrep/fao/009/a0512e/a0512e00.pdf. (Accessed 6 May 2008.)

32. FAO/WHO. 2002. Guidelines for the Evaluation of Probiotics in Food. Food and Agriculture Organization of the United Nations and World Health Organization Working Group Report. ftp://ftp.fao.org/docrep/fao/009/a0512e/a0512e00.pdf. (Accessed 6 May 2008.)

33. Ferris, D. G.,, C. Dekle, and, M. S. Litaker. 1996. Women’s use of over-the-counter antifungal medications for gynecologic symptoms. J. Fam. Pract. 42: 595– 600.

34. Forney, L. J.,, J. A. Foster, and, W. Ledger. 2006. The vaginal flora of healthy women is not always dominated by Lactobacillus species. J. Infect. Dis. 194: 1468– 1469.

35. Foxman, B.,, S. D. Manning,, P. Tallman,, R. Bauer,, L. Zhang,, J. S. Koopman,, B. Gillespie,, J. D. Sobel, and, C. F. Marrs. 2002. Uropathogenic Escherichia coli are more likely than commensal E. coli to be shared between heterosexual sex partners. Am. J. Epidemiol. 156: 1133– 1140.

36. Fredricks, D. N.,, T. L. Fiedler, and, J. M. Marrazzo. 2005. Molecular identification of bacteria associated with bacterial vaginosis. N. Engl. J. Med. 353: 1899– 1911.

37. Gan, B. S.,, J. Kim.,, G. Reid,, P. Cadieux, and, J. C. Howard. 2002. Lactobacillus fermentum RC-14 inhibits Staphylococcus aureus infection of surgical implants in rats. J. Infect. Dis. 185: 1369– 1372.

38. Gardiner, G.,, C. Heinemann,, M. L. Baroja,, A. W. Bruce,, D. Beuerman,, J. Madrenas,, and G. Reid. 2002. Oral administration of the probiotic combination Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 for human intestinal applications. Int. Dairy J. 12: 191– 196.

39. Gardner, H. L., and, C. D. Dukes. 1954. New etiologic agent in nonspecific bacterial vaginitis. Science 120:853.

40. Hatch, M.,, J. Cornelius,, M. Allison,, H. Sidhu,, A. Peck, and, R. W. Freel. 2006. Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int. 69: 691– 698.

41. Heinemann, C.,, J. E. van Hylckama Vlieg,, D. B. Janssen,, H. J. Busscher,, H. C. van der Mei, and G. Reid. 2000. Purification and characterization of a surface-binding protein from Lactobacillus fermentum RC-14 inhibiting Enterococcus faecalis 1131 adhesion. FEMS Microbiol. Lett. 190: 177– 180.

42. Hill, J. E.,, S. H. Goh,, D. M. Money,, M. Doyle,, A. Li,, W. L. Crosby,, M. Links,, A. Leung,, D. Chan, and, S. M. Hemmingsen. 2005. Characterization of vaginal microflora of healthy, nonpregnant women by chaperonin-60 sequence-based methods. Am. J. Obstet. Gynecol. 193(3 Pt 1) : 682– 692.

43. Howard, J.,, C. Heinemann,, B. J. Thatcher,, B. Martin,, B. S. Gan,, and G. Reid. 2000. Identification of collagen-binding proteins in Lactobacillus spp. with surface-enhanced laser desorption/ionization-time of flight ProteinChip technology. Appl. Environ. Microbiol. 66: 4396– 4400.

44. Iannini, P.,, L. Mandell,, J. Felmingham,, G. Patou, and, G. S. Tillotson. 2006. Adverse cutaneous reactions and drugs: a focus on antimicrobials. J. Chemother. 18: 127– 139.

45. Jahic, M.,, M. Nurkic, and, Z. Fatusic. 2006. Association of the pH change of vaginal environment in bacterial vaginosis with presence of Enterococcus faecalis in vagina. Med. Arh. 60: 364– 368.

46. Jin, L.,, L. Tao,, S. I. Pavlova,, J. S. So,, N. Kiwanuka,, Z. Namukwaya,, B. A. Saberbein,, and M. Wawer. 2007. Species diversity and relative abundance of vaginal lactic acid bacteria from women in Uganda and Korea. J. Appl. Microbiol. 102: 1107– 1115.

47. Kelly, M. C.,, M. J. Mequio, and, V. Pybus. 2003. Inhibition of vaginal lactobacilli by a bacteriocin-like inhibitor produced by Enterococcus faecium 62–6: potential significance for bacterial vaginosis. Infect. Dis. Obstet. Gynecol. 11: 147– 156.

48. Kim, S. O.,, H. I. Sheik,, S.-D. Ha,, A. Martins,, and G. Reid. 2006. G-CSF mediated inhibition of JNK is a key mechanism for Lactobacillus rhamnosus-induced anti-inflammatory effects in macrophages. Cell. Microbiol. 8: 1958– 1971.

49. Kirjavainen, P. K.,, R. M. Laine,, D. Carter,, J.-A. Hammond,, and G. Reid. Expression of anti-microbial defense factors in vaginal mucosa following exposure to Lactobacillus rhamnosus GR-1. Int. J. Probiot., in press.

50. Klebanoff, M. A.,, J. R. Schwebke,, J. Zhang,, T. R. Nansel,, K. F. Yu, and, W. W. Andrews. 2004. Vulvovaginal symptoms in women with bacterial vaginosis. Obstet. Gynecol. 104: 267– 272.

51. Klotz, S. A.,, N. K. Gaur,, R. De Armond,, D. Sheppard,, N. Khardori,, J. E. Edwards, Jr.,, P. N. Lipke,, and M. El-Azizi. 2007. Candida albicans Als proteins mediate aggregation with bacteria and yeasts. Med. Mycol. 45: 363– 370.

52. Koehler, G., and, G. Reid. 2006. Mechanisms of probiotic interference with Candida albicans, abstr. C126. Abstr. 8th ASM Conf. Candida Candidiasis. American Society for Microbiology, Washington, DC.

53. Kontiokari, T.,, K. Sundqvist,, M. Nuutinen,, T. Pokka,, M. Koskela,, and M. Uhari. 2001. Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women. BMJ 322:1571.

54. Lee, S. J.,, Y. H. Shim,, S. J. Cho, and, J. W. Lee. 2007. Probiotics prophylaxis in children with persistent primary vesicoureteral reflux. Pediatr. Nephrol. 22: 1315– 1320.

55. Lieske, J. C.,, D. S. Goldfarb,, C. De Simone,, and C. Regnier. 2005. Use of a probiotic to decrease enteric hyperoxaluria. Kidney Int. 68: 1244– 1249.

56. Lima, K. C.,, L. R. Fava, and, J. F. Siqueira, Jr. 2001. Susceptibilities of Enterococcus faecalis biofilms to some antimicrobial medications. J. Endod. 27: 616– 619.

57. Lloyd, A. L.,, D. A. Rasko, and, H. L. Mobley. 2007. Defining genomic islands and uropathogen-specific genes in uropathogenic Escherichia coli. J. Bacteriol. 189: 3532– 3546.

58. Lowe, N. K., and, N. A. Ryan-Wenger. 2003. Military women’s risk factors for and symptoms of genitourinary infections during deployment. Mil. Med. 168: 569– 574.

59. Marrazzo, J. M.,, R. L. Cook,, H. C. Wiesenfeld,, P. J. Murray,, B. Busse,, M. Krohn, and, S. L. Hillier. 2006. Women’s satisfaction with an intravaginal Lactobacillus capsule for the treatment of bacterial vaginosis. J. Womens Health (Larchmt) 15: 1053– 1060.

60. Marrazzo, J. M.,, L. A. Koutsky,, D. A. Eschenbach,, K. Agnew,, K. Stine, and, S. L. Hillier. 2002. Characterization of vaginal flora and bacterial vaginosis in women who have sex with women. J. Infect. Dis. 185: 1307– 1313.

61. Marrs, C. F.,, L. Zhang, and, B. Foxman. 2005. Escherichia coli mediated urinary tract infections: are there distinct uropathogenic E. coli (UPEC) pathotypes? FEMS Microbiol. Lett. 252: 183– 190.

62. Martin, R.,, M. Olivares,, M. L. Marin,, L. Fernandez,, J. Xaus, and, J. M. Rodriguez. 2005. Probiotic potential of 3 lactobacilli strains isolated from breast milk. J. Hum. Lact. 21: 8– 17.

63. Mayer, R. 2007. Interstitial cystitis pathogenesis and treatment. Curr. Opin. Infect. Dis. 20: 77– 82.

64. McGroarty, J. A., and, G. Reid. 1988a. Detection of a lactobacillus substance which inhibits Escherichia coli. Can. J. Microbiol. 34: 974– 978.

65. McGroarty, J. A., and, G. Reid. 1988b. Inhibition of enterococci by Lactobacillus species in vitro. Microb. Ecol. Health Dis. 1: 215– 219.

66. McGroarty, J. A.,, L. Tomeczek,, D. G. Pond,, G. Reid, and, A. W. Bruce. 1992. Hydrogen peroxide production by Lactobacillus species, correlation with susceptibility to the spermicidal compound nonoxynol-9. J. Infect. Dis. 165: 1142– 1144.

67. Morelli, L.,, D. Zonenenschain,, M. Del Piano, and, P. Cognein. 2004. Utilization of the intestinal tract as a delivery system for urogenital probiotics. J. Clin. Gastroenterol. 38 (6 Suppl.) :S107–S110.

68. Ness, R. B.,, K. E. Kip,, D. E. Soper,, S. Hillier,, C. A. Stamm,, R. L. Sweet,, P. Rice, and, H. E. Richter. 2005. Bacterial vaginosis (BV) and the risk of incident gonococcal or chlamydial genital infection in a predominantly black population. Sex. Transm. Dis. 32: 413– 417.

69. Newman, D. 1915. The treatment of cystitis by intravesical injections of lactic Bacillus cultures. Lancet August 14: 330– 332.

70. Nugent, R. P.,, M. A. Krohn, and, S. L. Hillier. 1991. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J. Clin. Microbiol. 29: 297– 301.

71. Okawa, T.,, H. Niibe,, T. Arai,, K. Sekiba,, K. Noda,, S. Takeuchi,, S. Hashimoto,, and N. Ogawa. 1993. Effect of LC9018 combined with radiation therapy on carcinoma of the uterine cervix. A phase III, multicenter, randomized, controlled study. Cancer 72: 1949– 1954.

72. Ombrella, A. M.,, A. Belmonte,, M. G. Nogueras,, I. R. Abad,, E. G. Sutich, and, D. G. Dlugovitzky. 2006. Sialidase activity in women with bacterial vaginosis. Medicina (Buenos Aires) 66: 131– 134.

73. Onrust, S. V.,, H. M. Lamb, and, J. A. Balfour. 1998. Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections. Drugs 56: 895– 928.

74. Patel, V.,, H. A. Weiss,, B. R. Kirkwood,, S. Pednekar,, P. Nevrekar,, S. Gupte,, and D. Mabey. 2006. Common genital complaints in women: the contribution of psychosocial and infectious factors in a population-based cohort study in Goa, India. Int. J. Epidemiol. 35: 1478– 1485.

75. Pelucchi, C.,, C. Bosetti,, E. Negri,, M. Malvezzi, and, C. La Vecchia. 2006. Mechanisms of disease: the epidemiology of bladder cancer. Nat. Clin. Pract. Urol. 3: 327– 340.

76. Perez, P. F.,, J. Dorè,, M. Leclerc,, F. Levenez,, J. Benyacoub,, P. Serrant,, I. Segura-Roggero,, E. J. Schiffrin,, and A. Donnet-Hughes. 2007. Bacterial imprinting of the neonatal immune system: lessons from maternal cells? Pediatrics 119:e724–e732.

77. Rafal’skii, V. V. 2000. Drug reactions on antibiotics used in the treatment of urinary tract infections. Urologiia 6: 51– 55.

78. Reid, G.,, D. Beuerman,, C. Heinemann, and, A. W. Bruce. 2001a. Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora. FEMS Immunol. Med. Microbiol. 32: 37– 41.

79. Reid, G.,, A. W. Bruce,, N. Fraser,, C. Heinemann,, J. Owen,, and B. Henning. 2001b. Oral probiotics can resolve urogenital infections. FEMS Immunol. Med. Microbiol. 30: 49– 52.

80. Reid, G.,, A. W. Bruce, and, M. Taylor. 1992a. Influence of three day antimicrobial therapy and Lactobacillus suppositories on recurrence of urinary tract infection. Clin. Ther. 14: 11– 16.

81. Reid, G.,, A. W. Bruce, and, M. Taylor. 1995. Instillation of Lactobacillus and stimulation of indigenous organisms to prevent recurrence of urinary tract infections. Microecol. Ther. 23: 32– 45.

82. Reid, G.,, J. Burton,, J.-A. Hammond, and, A. W. Bruce. 2004. Nucleic acid based diagnosis of bacterial vaginosis and improved management using probiotic lactobacilli. J. Med. Food 7: 223– 228.

83. Reid, G.,, D. Charbonneau,, J. Erb,, B. Kochanowski,, D. Beuerman,, R. Poehner, and, A. W. Bruce. 2003a. Oral use of Lactobacillus rhamnosus GR-1 and L. fermentum RC-14 significantly alters vaginal flora: randomized, placebo-controlled trial in 64 healthy women. FEMS Immunol. Med. Microbiol. 35: 131– 134.

84. Reid, G.,, D. Charbonneau,, S. Gonzalez,, G. Gardiner,, J. Erb, and, A. W. Bruce. 2002. Ability of Lactobacillus GR-1 and RC-14 to stimulate host defences and reduce gut translocation and infectivity of Salmonella typhimurium. Nutraceut. Food 7: 168– 173.

85. Reid, G.,, R. L. Cook, and, A. W. Bruce. 1987. Examination of strains of lactobacilli for properties which may influence bacterial interference in the urinary tract. J. Urol. 138: 330– 335.

86. Reid, G.,, P. L. Cuperus,, A. W. Bruce,, L. Tomeczek,, H. C. van der Mei,, A. H. Khoury, and, H. J. Busscher. 1992b. Comparison of contact angles and adhesion to hexadecane of urogenital, dairy and poultry lactobacilli: effect of serial culture passages. Appl. Environ. Microbiol. 58: 1549– 1553.

87. Reid, G., J.-A. Hammond, and, A. W. Bruce. 2003b. Effect of lactobacilli oral supplement on the vaginal microflora of antibiotic treated patients: randomized, placebo-controlled study. Nutraceut. Food 8: 145– 148.

88. Reid, G.,, J. A. McGroarty,, P. A., G. Domingue,, A. W. Chow,, A. W. Bruce,, A. Eisen, and, J. W. Costerton. 1990. Coaggregation of urogenital bacteria in vitro and in vivo. Curr. Microbiol. 20: 47– 52.

89. Reid, G.,, M. L. Zorzitto,, A. W. Bruce,, M. A., S. Jewett,, R. C. Y. Chan, and, J. W. Costerton. 1984. The pathogenesis of urinary tract infection in the elderly: the role of bacterial adherence to uroepithelial cells. Curr. Microbiol. 11: 67– 72.

90. Saunders, S. G.,, A. Bocking,, J. Challis, and, G. Reid. 2007. Disruption of Gardnerella vaginalis biofilms by Lactobacillus. Coll. Surf. B 55: 138– 142.

91. Scelo, G., and, P. Brennan. 2007. The epidemiology of bladder and kidney cancer. Nat. Clin. Pract. Urol. 4: 205– 217.

92. Schwebke, J. R., and, R. Desmond. 2007. A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases. Am. J. Obstet. Gynecol. 196:517.e 1– 6.

93. Schwiertz, A.,, D. Taras,, K. Rusch, and, V. Rusch. 2006. Throwing the dice for the diagnosis of vaginal complaints? Ann. Clin. Microbiol. Antimicrob. 5:4.

94. Sewankambo, N.,, R. H. Gray,, M. J. Wawer,, L. Paxton,, D. McNaim,, F. Wabwire-Mangen,, D. Serwadda,, C. Li,, N. Kiwanuka,, S. L. Hillier,, L. Rabe,, C. A. Gaydos,, T. C. Quinn,, and J. Konde-Lule. 1997. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet 350: 546– 550.

95. Sha, B. E.,, H. Y. Chen,, Q. J. Wang,, M. R. Zariffard,, M. H. Cohen, and, G. T. Spear. 2005. Utility of Amsel criteria, Nugent score, and quantitative PCR for Gardnerella vaginalis, Mycoplasma hominis, and Lactobacillus spp. for diagnosis of bacterial vaginosis in human immunodeficiency virus-infected women. J. Clin. Microbiol. 43: 4607– 4612.

96. Sihvo, S.,, R. Ahonen,, H. Mikander, and, E. Hemminki. 2000. Self-medication with vaginal antifungal drugs: physicians’ experiences and women’s utilization patterns. Fam. Pract. 17: 145– 149.

97. Spiegel, C. A. 1991. Bacterial vaginosis. Clin. Microbiol. Rev. 4: 485– 502.

98. Stoyancheva, G. D.,, S. T. Danova, and, I. Y. Boudakov. 2006. Molecular identification of vaginal lactobacilli isolated from Bulgarian women. Antonie Leeuwenhoek 90: 201– 210.

99. Sumeksri, P.,, C. Koprasert, and, S. Panichkul. 2005. BVBLUE test for diagnosis of bacterial vaginosis in pregnant women attending antenatal care at Phramongkutklao Hospital. J. Med. Assoc. Thai. 88(Suppl. 3) :S7–S13.

100. Tendolkar, P. M.,, A. S. Baghdayan, and, N. Shankar. 2003. Pathogenic enterococci: new developments in the 21st century. Cell. Mol. Life Sci. 60: 2622– 2636.

101. Thanavuth, A.,, A. Chalermchockcharoenkit,, D. Boriboonhirunsarn,, R. Sirisomboon, and, K. Pimol. 2007. Prevalence of bacterial vaginosis in Thai pregnant women with preterm labor in Siriraj hospital. J. Med. Assoc. Thai. 90: 437– 441.

102. Theoharides, T. C. 2007. Treatment approaches for painful bladder syndrome/interstitial cystitis. Drugs 67: 215– 235.

103. Thies, F. L.,, W. Konig, and, B. Konig. 2007. Rapid characterization of the normal and disturbed vaginal microbiota by application of 16S rRNA gene terminal RFLP fingerprinting. J. Med. Microbiol. 56(Pt. 6) : 755– 761.

104. Tomeczek, L.,, G. Reid,, P. L. Cuperus,, J. A. McGroarty,, H. C. van der Mei,, A. W. Bruce,, A. H. Khoury,, and H. J. Busscher. 1992. Correlation between hydrophobicity and resistance to nonoxynol-9 and vancomycin for urogenital isolates of lactobacilli. FEMS Microbiol. Lett. 94: 101– 104.

105. Uehara, S.,, K. Monden,, K. Nomoto,, Y. Seno,, R. Kariyama,, and H. Kumon. 2006. A pilot study evaluating the safety and effectiveness of Lactobacillus vaginal suppositories in patients with recurrent urinary tract infection. Int. J. Antimicrob. Agents 28(Suppl. 1) :S30–S34.

106. Vasquez, A.,, T. Jakobsson,, S. Ahrne,, U. Forsum, and, G. Molin. 2002. Vaginal Lactobacillus flora of healthy Swedish women. J. Clin. Microbiol. 40: 2746– 2749.

107. Velraeds, M. M.,, van de Belt-Gritter, H. C. van der Mei,, G. Reid, and, H. J. Busscher. 1998. Interference in initial adhesion of uropathogenic bacteria and yeasts to silicone rubber by a Lactobacillus acidophilus biosurfactant. J. Med. Microbiol. 47: 1081– 1085.

108. Velraeds, M. M.,, H. C. van der Mei,, G. Reid, and, H. J. Busscher. 1996. Inhibition of initial adhesion of uropathogenic Enterococcus faecalis by biosurfactants from Lactobacillus isolates. Appl. Environ. Microbiol. 62: 1958– 1963.

109. von Graevenitz, A. 1982. Pathogenicity of enterococci outside of urinary tract and blood stream. Klin. Wochenschr. 60: 696– 698.

110. Wheeler, C. M. 2007. Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing. Nat. Clin. Pract. Oncol. 4: 224– 235.

111. WHO. 1946. Constitution of the World Health Organization, Geneva, 1946. http://www.who.int/about/definition/en/print.html. Accessed 30 October 2006.

112. Yeganegi, M.,, G. Reid,, J. R., G. Challis, and, A. Bocking. 2007. Lactobacilli supernatant inhibits TNFα production and COX2 expression in LPS-activated placental trophoblasts, abstr. 55, p. 20. Abstr. 2007 SGI Annu. Sci. Mtg.

113. Yoon, S. S., and, D. J. Hassett. 2004. Chronic Pseudomonas aeruginosa infection in cystic fibrosis airway disease: metabolic changes that unravel novel drug targets. Expert Rev. Anti Infect. Ther. 2: 611– 623.

114. Zarate, G., and, M. E. Nader-Macias. 2006. Influence of probiotic vaginal lactobacilli on in vitro adhesion of urogenital pathogens to vaginal epithelial cells. Lett. Appl. Microbiol. 43: 174– 180.

115. Zhong, W.,, K. Millsap,, H. Bialkowska-Hobrzanska, and, G. Reid. 1998. Differentiation of Lactobacillus species by molecular typing. Appl. Environ. Microbiol. 64: 2418– 2423.

Tables

Probiotics and Diseases of the Genitourinary Tract

/content/10.1128/9781555815462.ch21.ch21table01

Table 1

Diseases of the urogenital tract for which there is a rationale for probiotics or evidence that probiotics are effective

Table 1

Diseases of the urogenital tract for which there is a rationale for probiotics or evidence that probiotics are effective